finerenone Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).   Wikipedia

Chemistry

  • SMILES: CCOc1ncc(C)c2NC(=C([C@@H](c3ccc(cc3OC)C#N)c12)C(=O)N)C
  • InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
  • Mol. Mass: 378.43
  • ALogP: 2.99
  • ChEMBL Molecule:
    finerenone  
More Chemistry

Pharmacology

Alternative names

bay 94-8862 | finerenone

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 3)

Heart Failure (Phase 3)

Pharmacokinetics (Phase 1)

Pharmacology, Clinical (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue